🏛️ Company factsSEC filings + FINRA official data
Annual revenue $36.8B · latest quarter up 9.5% YoY · profitable (FY net income $7.7B) · short activity below its recent average — bears covering.
FY revenue
$36.8B
2025-12
Latest Q YoY
+9.5%
Gross margin
18.6%
FY net income
$7.7B
Diluted EPS
$14.33
Short volume
41%
20d avg 51.4% · shorts covering
🐋 5%+ ownership filings (last 180d)
The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.
- 2026-05-14passive (13G)Capital World Investors
- 2026-04-29passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
- 2026-03-26passive (13G)VANGUARD GROUP INC
🎯 Market expectations
Expectation reliability High · 77/100Nasdaq analyst consensus · the pre-news baseline
- Jun 2026$6.29 vs $5.60+12.32%
- Mar 2026$5.15 vs $4.73+8.88%
- Dec 2025$5.29 vs $4.76+11.13%
- Sep 2025$5.64 vs $5.00+12.8%
The takeaway
This company habitually beats by +11.3% — the next report has to clear that bar to count as good news.
Analyst estimates, not our forecast · not investment advice
What's moving this stock lately
4 direct · 2 2nd-order · 0 thematicRanked by impact strength · strength = estimated move × freshness decay (shorter-lived effects decay faster)
- #1▲2.37%DirectAMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE13d ago
Repatha could expand into primary prevention, widening its market, though the impact is modest against $36.8B total revenue
Also named: REGN · NVS · ESPR
- #2▼0.81%2nd-orderSandisk, Marvell, Robinhood, Novartis, Dell, and More Stocks That Explain Today's Market11d ago
Novartis's advance in the relevant therapeutic area could weigh on market-share expectations for competing drugs
Also named: SNDK · MRVL · DELL · WDC · MU · HOOD
- #3▼0.63%2nd-orderRevolution Medicines: Strong Buy RASONQUE FDA Approval And Zoldonrasib PDAC Expansions13d ago
Its Lumakras (sotorasib) faces long-term competition from RVMD's broader RAS(ON) platform, though Lumakras is a small share of Amgen's revenue, limiting the marginal impact.
Also named: RVMD · BMY
The early decline is largely already in the price with no specific catalyst disclosed, likely reflecting lingering drug-pricing policy and biosimilar competition concerns
Also named: NVS · PFE · PANW · CRWD · ZS · BE
- #5▲0.21%DirectJim Cramer says investors are too focused on AI stocks. Here's where he says to look instead4d ago
Named as a defensive biotech value pick; the company has steadily beaten estimates by about 11% recently, so this commentary alone is not new information
Also named: BA · GE · ENB · EPD · WMB · HOOD
- #6▲0.18%DirectTake the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus4d ago
Only cited as a focus stock with no new results or catalyst; its consistent history of beating estimates is already priced in, so sentiment-driven mention has minimal impact.
Also named: DGX · LNG · NGL · FDS · LRN · ECDP
🕰️ Price × news · engine report card
Drag to pan, scroll to zoom · real daily bars and volume
📜 Call history (newest first
19 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view
Sign up · free 7-day trial →Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.
Sign up · free 7-day trial →